[go: up one dir, main page]

WO2003006973A1 - Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede - Google Patents

Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede Download PDF

Info

Publication number
WO2003006973A1
WO2003006973A1 PCT/US2002/019813 US0219813W WO03006973A1 WO 2003006973 A1 WO2003006973 A1 WO 2003006973A1 US 0219813 W US0219813 W US 0219813W WO 03006973 A1 WO03006973 A1 WO 03006973A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
sample
profile
specimen
data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019813
Other languages
English (en)
Inventor
Edward E Patz, Jr.
Michael J. Campa
Michael C. Fitzgerald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to EP02744533A priority Critical patent/EP1415141A1/fr
Priority to CA002453546A priority patent/CA2453546A1/fr
Publication of WO2003006973A1 publication Critical patent/WO2003006973A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Definitions

  • the data output from the mass spectrometry is an array, or spectrum, of peaks with each peak representing a protein or group of proteins present in a given sample.
  • the location of any given peak on the x-axis is related to the molecular mass and charge of the protein, while the height of the peak is associated with the relative abundance of the protein ion.
  • the spectrum represents a molecular profile of the protein sub-group or fraction of the expressed proteins in a given specimen.
  • the subject characteristics are input to the cell protein data processing unit 130 with input unit 140.
  • Input unit 140 is suitably a computer that stores subject information.
  • ProteinChipTM One of the differences between SELDI and conventional MALDI-TOF is the ProteinChipTM technology for sample application.
  • ProteinChips are available with a variety of chemical surfaces, which permits the capture and analysis of whole classes of proteins based on their charge, hydrophobicity, or metal binding capablity.
  • the analysis of a biological specimen using just one surface may give information on 40-60 different proteins.
  • sample preparation and analysis must be optimized for each ProteinChip surface and for each sample type.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Bioethics (AREA)
  • Molecular Biology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un système de profilage de protéines cellulaires et de diagnostic qui fractionne (110) le contenu protéique d'un échantillon de tissu en sous-groupes de protéines, qui effectue indépendamment une spectroscopie de masse (120) sur chaque sous-groupe de protéines, qui tire un profil de protéine d'expression cellulaire du spectre de masse et qui identifie des motifs protéiques associés aux caractéristique du sujet, telles que des conditions biologiques et des maladies, sur la base du profil de protéine d'expression cellulaire. Dans un mode de réalisation, les motifs protéiques sont identifiés au moyen d'un réseau neural artificiel ou d'autres techniques d'exploration de données ou de reconnaissance de motifs.
PCT/US2002/019813 2001-07-12 2002-07-12 Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede Ceased WO2003006973A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02744533A EP1415141A1 (fr) 2001-07-12 2002-07-12 Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede
CA002453546A CA2453546A1 (fr) 2001-07-12 2002-07-12 Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/902,786 US20030013120A1 (en) 2001-07-12 2001-07-12 System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
US09/902,786 2001-07-12

Publications (1)

Publication Number Publication Date
WO2003006973A1 true WO2003006973A1 (fr) 2003-01-23

Family

ID=25416390

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019813 Ceased WO2003006973A1 (fr) 2001-07-12 2002-07-12 Systeme et procede d'expression proteique differentielle et programme et procede de decouverte au moyen d'un biomarqueur de diagnostic utilisant lesdits systeme et procede

Country Status (4)

Country Link
US (2) US20030013120A1 (fr)
EP (1) EP1415141A1 (fr)
CA (1) CA2453546A1 (fr)
WO (1) WO2003006973A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1685259A4 (fr) * 2003-10-23 2007-12-12 Univ Pittsburgh Biomarqueurs de la sclerose laterale amyotrophique
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808836D0 (en) * 1998-04-27 1998-06-24 Amersham Pharm Biotech Uk Ltd Microfabricated apparatus for cell based assays
US7261859B2 (en) 1998-12-30 2007-08-28 Gyros Ab Microanalysis device
SE0001790D0 (sv) * 2000-05-12 2000-05-12 Aamic Ab Hydrophobic barrier
EP1384076B1 (fr) 2001-03-19 2012-07-25 Gyros Patent Ab Caracterisation de variables de reaction
US6919058B2 (en) 2001-08-28 2005-07-19 Gyros Ab Retaining microfluidic microcavity and other microfluidic structures
WO2003082730A1 (fr) * 2002-03-31 2003-10-09 Gyros Ab Dispositifs microfluidiques efficaces
WO2004089972A2 (fr) * 2003-04-02 2004-10-21 Merck & Co., Inc. Techniques d'analyse de donnees de spectrometrie de masse
US20040236603A1 (en) * 2003-05-22 2004-11-25 Biospect, Inc. System of analyzing complex mixtures of biological and other fluids to identify biological state information
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
EP1718327B1 (fr) * 2003-06-20 2015-01-07 University of Florida Biomarqueurs permettant de differencier des diabetes de types 1 et 2
US20090010819A1 (en) * 2004-01-17 2009-01-08 Gyros Patent Ab Versatile flow path
WO2006075966A1 (fr) * 2005-01-17 2006-07-20 Gyros Patent Ab Parcours d'ecoulement polyvalent
CA2563847A1 (fr) 2004-04-20 2005-11-03 Board Of Regents, The University Of Texas System Utilisation de motif proteomique de plasma aux fins de diagnostic, classification, prevision de reponse a un traitement et un comportement clinique, stratification de traitement et surveillance de la maladie dans le cas de malignites hematologiques
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20060084126A1 (en) * 2004-10-20 2006-04-20 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
JP2009537565A (ja) 2006-05-16 2009-10-29 ノップ ニューロサイエンシーズ、インク． Ｒ（＋）およびｓ（−）プラミペキソール組成とそれを利用する方法
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (fr) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthese de benzothiazole diamines substituees et purifiees du point de vue chiral
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
US20100099135A1 (en) * 2008-10-22 2010-04-22 Mandy Katz-Jaffe Methods and assays for assessing the quality of embryos in assisted reproduction technology protocols
KR101114228B1 (ko) * 2009-06-01 2012-03-05 한국기초과학지원연구원 데이터 비의존성 분석법과 데이터 의존성 분석법을 복합화한 단백질 분석방법
KR101135048B1 (ko) 2011-05-19 2012-04-13 한국기초과학지원연구원 데이터 비의존성 분석법과 데이터 의존성 분석법을 복합화한 단백질 분석방법
WO2013096816A1 (fr) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Synthèse améliorée de composés substitués par amine de 4,5,6,7-tétrahydrobenzothiazole
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CA2918035C (fr) 2013-07-12 2023-01-03 Knopp Biosciences Llc Utilisation de dexpramipexole dans le traitement de troubles associes a de hauts taux d'eosinophiles et/ou de basophiles
PL3033081T3 (pl) 2013-08-13 2021-08-30 Knopp Biosciences Llc Kompozycje i sposoby do leczenia przewlekłej pokrzywki
US9642840B2 (en) 2013-08-13 2017-05-09 Knopp Biosciences, Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
WO2015109263A2 (fr) 2014-01-17 2015-07-23 University Of Washington Biomarqueurs pour la détection et la surveillance du cancer du côlon
CN106021988A (zh) * 2016-05-26 2016-10-12 河南城建学院 蛋白质复合物的识别方法
MY202410A (en) 2017-09-01 2024-04-27 Venn Biosciences Corp Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
AU2020326698A1 (en) 2019-08-05 2022-02-24 Seer, Inc. Systems and methods for sample preparation, data generation, and protein corona analysis
CN112485322B (zh) * 2020-12-01 2022-02-11 南京医科大学 精浆细胞外囊泡slc5a12蛋白的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005553A1 (fr) * 1995-07-25 1997-02-13 Horus Therapeutics, Inc. Procedes de diagnostic de maladies assiste par ordinateur
US5687716A (en) * 1995-11-15 1997-11-18 Kaufmann; Peter Selective differentiating diagnostic process based on broad data bases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856112A (en) * 1994-06-16 1999-01-05 Urocor, Inc. Method for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US6043044A (en) * 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005553A1 (fr) * 1995-07-25 1997-02-13 Horus Therapeutics, Inc. Procedes de diagnostic de maladies assiste par ordinateur
US5687716A (en) * 1995-11-15 1997-11-18 Kaufmann; Peter Selective differentiating diagnostic process based on broad data bases

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1685259A4 (fr) * 2003-10-23 2007-12-12 Univ Pittsburgh Biomarqueurs de la sclerose laterale amyotrophique
US7858071B2 (en) 2003-10-23 2010-12-28 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for amyotrophic lateral sclerosis
US8202510B2 (en) 2003-10-23 2012-06-19 University of Pittsburgh—of the Commonwealth System of Higher Education Biomarkers for amyotrophic lateral sclerosis
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Also Published As

Publication number Publication date
US20040005634A1 (en) 2004-01-08
EP1415141A1 (fr) 2004-05-06
US20030013120A1 (en) 2003-01-16
CA2453546A1 (fr) 2003-01-23

Similar Documents

Publication Publication Date Title
US20030013120A1 (en) System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
Schwartz et al. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression
Pusch et al. Mass spectrometry-based clinical proteomics
Veenstra et al. Proteomic patterns for early cancer detection
Bowler et al. Proteomics in pulmonary medicine
EP3260866B1 (fr) Nouveaux biomarqueurs de déficience cognitive et procédés permettant de détecter une déficience cognitive au moyen de tels biomarqueurs
KR101645841B1 (ko) 인간 폐조직 병변의 지표가 되는 인간 혈청 내 단백질의 동정
JP2009540319A (ja) 質量分析バイオマーカーアッセイ
JP2006522340A (ja) 質量分析データの分析法
US20060064253A1 (en) Multiple high-resolution serum proteomic features for ovarian cancer detection
JP2006510875A (ja) コンステレーションマッピングおよびそれらの使用
WO2005008247A2 (fr) Detection d'une pathologie de l'endometre
Ding et al. Protein biomarkers in serum of patients with schizophrenia
US7485852B2 (en) Mass analysis method and mass analysis apparatus
US7955862B2 (en) Method and device for the qualitative and/or quantitative determination of a protein and/or peptide pattern of a fluid sample, which has been taken from a human or animal body
Bhattacharyya et al. Biomarkers that discriminate Multiple Myeloma Patients With or Without Skeletal Involvement Detected Using SELDI‐TOF Mass Spectrometry and Statistical and Machine Learning Tools
US20070059842A1 (en) Mass analysis method and mass analysis apparatus
EP1887351A1 (fr) Procede de criblage pour une proteine specifique dans une analyse detaillee du proteome
US20050106104A1 (en) Methods for diagnosing cardiovascular disorders
CN112630344B (zh) 代谢标志物在脑梗死中的用途
CN112305120B (zh) 代谢物在动脉粥样硬化性脑梗死中的应用
CN112630330B (zh) 小分子物质在脑梗死诊断中的应用
US7576323B2 (en) Point-of-care mass spectrometer system
JP2020193901A (ja) マーカ物質の探索支援方法、探索支援プログラムおよび探索支援装置
Conrads et al. Mass Spectrometry‐Based Proteomic Approaches for Disease Diagnosis and Biomarker Discovery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2453546

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002744533

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002744533

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002744533

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP